CNSide Diagnostics recently attended the NCCN 2026 Breast Cancer Conference hosted by the National Comprehensive Cancer Network to connect with clinicians, researchers, and oncology professionals focused on advancing breast cancer care.

During the event, the CNSide team shared the latest updates and upcoming milestones related to the CNSide Cerebrospinal Fluid (CSF) Assay Platform, which is designed to support physicians evaluating patients with suspected Leptomeningeal Metastases.

Addressing the Diagnostic Challenges of Leptomeningeal Metastases

Leptomeningeal metastases (LM) occur when cancer cells spread to the leptomeninges, the membranes that surround the brain and spinal cord. This condition is a serious complication that can arise from advanced cancers, including:

• Breast Cancer
• Lung Cancer
• Melanoma

Diagnosing LM can be complex, as symptoms often vary and traditional diagnostic approaches may not always detect disease early. Advances in cerebrospinal fluid diagnostics and tumor cell analysis are helping clinicians gain more detailed insights into disease presence and progression.

The CNSide Cerebrospinal Fluid Assay Platform

The CNSide CSF Assay Platform is designed to analyze tumor cells and molecular markers present in cerebrospinal fluid, providing physicians with additional diagnostic information that may help guide patient management.

Innovations in CSF-based testing are becoming increasingly important as clinicians seek more precise ways to evaluate central nervous system involvement in cancer and tailor treatment strategies accordingly.

By enabling more detailed analysis of tumor cells circulating in the cerebrospinal fluid, advanced diagnostic platforms have the potential to support earlier detection and better characterization of disease affecting the central nervous system.

Engaging the Oncology Community

Events like the NCCN 2026 Breast Cancer Conference provide valuable opportunities for collaboration across the oncology community.

The CNSide team appreciated the opportunity to connect with physicians, researchers, and healthcare professionals who stopped by the booth to learn more about the platform and discuss the evolving landscape of diagnostics for central nervous system metastases.

Continued dialogue between clinicians, researchers, and diagnostic innovators is essential for improving care for patients facing complex conditions such as leptomeningeal metastases.

Learn More

To learn more about CNSide Diagnostics and its work advancing diagnostics for cancers affecting the central nervous system, you can browse our website.